Skip to content
RecruitingPhase 2

Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial

NCT06405607 · Psi or Ket · University of Iowa

Recruiting
Status
Accepting participants
Phase 2
Phase
80
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

This study will collect data that measures the effects of a psychedelic intervention on patients struggling with alcohol use disorder (AUD). The study design will be a double blind, randomized, active-comparator trial with two study arms. Subjects randomized to Arm 1 (n=40) will receive individual psychotherapy sessions plus a 30 mg dose of psilocybin. Arm 2 subjects (n=40) will receive individual psychotherapy sessions and a 0.75 mg/kg dose of ketamine.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Timeline Follow-Back for Alcohol to assess change

    Measured over Weekly, over the course of 16 weeks

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

21 Years to 65 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion criteria: * Weight between 50kg and 150kg * No known allergies to rescue medication * For people capable of becoming pregnant, not pregnant and using contraception * Not currently breastfeeding * Meets criteria for DSM-V moderate to severe AUD. * Have at least 4 heavy drinking days (5 or more standard drinks in a day) in the past 30 days. * Not currently participating in formal treatment for AUD. * No history of a of cerebrovascular accident, asthma, or significant alcohol withdrawal history * No seizure disorder, coronary artery disease, heart failure, uncontrolled hypertension, insulin-dependent diabetes, pancreatitis, liver disease * No hallucinogen or ketamine use in past 12 months * No self-reported, personal, or familial history of specific psychotic disorders/episodes. * No serious traumatic brain injury (TBI) in the past 2 years * No substance use disorder other than AUD over the past 12 months * If taking a GLP-1 agonist, stable dosage for past 3 months * Family member/friend for pick-up, overnight post-drug session monitoring. * No MRI contraindications Exclusion Criteria: Drug/medication assessment that yields: nonprescription medication use, nutritional supplement, or herbal supplement (except when approved by the study investigators), medically unstable, current medication use that has significant potential to interact with study drug (e.g., antidepressants, antipsychotics, psychostimulants, treatments for addictions, other dopaminergic or serotonergic agents, lithium, anticonvulsants, or benzodiazepines). Psychiatric assessment that yields:1) history of severe suicide attempt, 2) current suicidality 3) first-degree relative with schizophrenia or schizoaffective disorder, 4) comorbid substance use disorder including cocaine, psychostimulant, or opioid use disorder within past 12 months 5) history of co-occurring psychotic episode/diagnosis including schizophrenia, schizoaffective disorder, schizophreniform, substance-induced psychosis, delusional disorder, or psychosis not otherwise specified, 6) high risk of adverse emotional or behavioral reaction based on the medical monitor's clinical evaluation that may also yield evidence of serious current stressors, a lack of meaningful social support, antisocial behavior, and/or serious personality disorders amongst other conditions. Medical assessment that yields: serious ECG abnormalities (evidence of ischemia, myocardial infarction, QTc prolongation \[QTc \> .045\]), serious abnormalities of complete blood count or chemistries, medical conditions that would preclude safe participation (significantly impaired liver function), or pregnancy. MRI contraindication (pacemaker, etc.)

Where

1 study site

FacilityCityRegionCountry
University of Iowa Health CareIowa CityIowaUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT06405607 on ClinicalTrials.gov →

Last updated in the registry 2025-11-28. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits